UNSPSC 51273607: Cocaine hydrochloride

This classification denotes a cns stimulant with the molecular formula C17H21NO4.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier XH8T8T6WZH, chemically known as 1.alpha.h,5.alpha.h-tropane-2.beta.-carboxylic acid, 3.beta.-hydroxy-, methyl ester, benzoate (ester), hydrochloride but more generally known as cocaine hydrochloride, which bears US NIH Compound Identifier 2826. European Medicines Agency schedules Cocaine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13417MIG.

UNSPSC 51273607 Cocaine hydrochloride is a Commodity code that does not align with the recent state and local procurement activity tagged under it. The three most recent opportunities — a Seminole County naloxone and drug deactivation systems purchase, a Texas HHS pharmacy benefit initiative RFI, and a Minnesota multistate cooperative pharmaceutical and OTC product contract — involve naloxone (an opioid antagonist), pharmacy benefit management, and generic pharmaceuticals, none of which correspond to cocaine hydrochloride procurement. State and local governments do not appear to be actively soliciting cocaine hydrochloride through public contracting channels; the code shows a fundamental mismatch between its nominal scope and actual buying activity.

The recent activity under this code reflects health agencies and cooperative purchasing organizations sourcing harm-reduction supplies, prescription fulfillment services, and generic drug inventories rather than scheduled pharmaceutical precursors. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries and a due date of July 26, 2023 (the posting date and response deadline conflict in the source). The Texas Health and Human Services Commission posted an RFI in April 2026 to gather vendor capabilities for direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager arrangements. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued an RFP in January 2026 for generic multi-source pharmaceuticals and OTC products with proposals due March 26, 2026, leveraging three authorized wholesalers and requiring NDC coding, cGMP certification, and Drug Supply Chain Security Act compliance. This code warrants close monitoring for mislabeling — if it receives future opportunities, they should be evaluated for actual relevance to cocaine procurement before pursuing.